Intellect Neuroscience

Intellect Neuroscience is a biopharmaceutical company that was primarily engaged in the discovery and development of disease-modifying therapeutic agents for Alzheimer's disease and other neurodegenerative disorders. The company's business model centered on its proprietary platform technologies, including ANTISENILIN for monoclonal antibodies, RECALL-VAX for therapeutic vaccines, and CONJUMAB for antibody-drug conjugates. Intellect successfully licensed its ANTISENILIN intellectual property to several major pharmaceutical companies for the development of amyloid-beta targeting antibodies. While the company reached clinical stages with its lead candidate OX1 for Friedreich's ataxia, it has faced significant financial difficulties and is currently considered inactive in its operations. Its legacy remains tied to the foundational patents it held for immunotherapy approaches in neurology.